TheraRadar
← Back
Data updated: Mar 29, 2026

HIBROW HLTHCARE

NeurologyCardiovascularOphthalmology
Generics

HIBROW HLTHCARE is a generic drug manufacturer focused on Neurology, Cardiovascular, Ophthalmology.

2016
Since
18
Drugs
-
Trials
404
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

FLUDROCORTISONE ACETATE 2026-02-10
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 40%
2 drugs
Cardiovascular 20%
1 drugs
Ophthalmology 20%
1 drugs
Metabolic 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

UPJOHN big-pharma
Neurology, Cardiovascular, Metabolic, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology, Metabolic
B BRAUN specialty
Ophthalmology, Metabolic, Cardiovascular
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Neurology
Novartis big-pharma
Cardiovascular, Ophthalmology